Register entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 12
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 2 human prescription drug. By marketing category: NDA 2.
| Dosage form | NDCs |
|---|---|
| solution/ drops | 1 |
| spray | 1 |
| Route | NDCs |
|---|---|
| nasal | 1 |
| ophthalmic | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| oyster point pharma, inc. | 2 |
Exclusivity
Patents and exclusivities
12| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10456396 | TYRVAYAvarenicline tartrate | product | Oct 2035 |
| 11224598 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 11903941 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 11903942 | TYRVAYAvarenicline tartrate | product | Oct 2035 |
| 11903943 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 11911380 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 12576080 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 12653824 | TYRVAYAvarenicline tartrate | product | Oct 2035 |
| 9504644 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 9504645 | TYRVAYAvarenicline tartrate | product | Oct 2035 |
| 9532944 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
| 9597284 | TYRVAYAvarenicline tartrate | use | Oct 2035 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Ryzumvi | phentolamine mesylate | solution/ drops, ophthalmic | 83368-075NDA |
| Tyrvaya | varenicline | spray, nasal | 73521-030NDA |
Enquiry
Common questions
- Is Oyster Point Pharma, Inc. FDA approved?
- Oyster Point Pharma, Inc. holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Oyster Point Pharma, Inc. make?
- 2 products are listed under Oyster Point Pharma, Inc. in the openFDA NDC Directory, most often as solution/ drops; spray. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.